News for SELLAS Life Sciences Group, Inc. (SLS)

SELLAS Life Sciences Group (NASDAQ: SLS) to present preclinical efficacy data of SLS009 at ASCO 2025. The presentation will focus on ASXL1 mutated colorecta

**media[603414]**

Late-stage clinical biopharmaceutical company Sellas Life Sciences Group, Inc. (SLS) Tuesday announced positive survival in Cohort 3 data from the ongoing Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia.

**media[589210]**

”“ Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Fin

Get insights into SELLAS Life Sciences' FY earnings. GAAP EPS outperforms estimates by $0.04.

**media[572457]**

PR NewswireVANCOUVER, BC, Feb. 27, 2025 USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 27, 2025 /PRNewswire/ -- US

**media[545781]**

**media[526616]**

SELLAS Life Sciences (SLS) stock falls following interim results from a Phase 3 REGAL trial for its lead asset, galinpepimut-S (GPS) in blood cancer. Read more here.

**media[522508]**

**media[509364]**

**media[504199]**

NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. ( SLS) (”œSELLAS” or the ”œCompany”), a late-stage clinical biopharmaceutic

**media[487309]**

- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venet

SELLAS reports promising AML drug trial results

**media[477617]**